What Wegovy does to your stomach, step by step

Step 1: the slow-down that starts before you finish eating

Wegovy's active ingredient, semaglutide, mimics a gut hormone called GLP-1 that your body releases naturally after a meal. One of GLP-1's jobs is to send a signal to the stomach to slow gastric emptying, the process by which digested food moves through into the small intestine. When that process slows, the stomach stays fuller for longer after each meal, and the cues that usually trigger hunger take longer to return.

This is not a side effect. It is the mechanism. Food sitting in the stomach for a longer period than usual is why many people on Wegovy find that a smaller plate is genuinely enough, without the willpower effort that calorie restriction alone requires. The NHS explains this effect on its semaglutide medicines page.

There is a common misconception worth setting aside here: some people assume Wegovy works by shrinking the stomach physically, as a surgical procedure would. It does not. The stomach's size stays the same. What changes is the speed of emptying and the strength of the appetite signal, both driven by GLP-1 receptor activity, not anatomy. If you want a more detailed look at the anatomical question, the page on whether Wegovy shrinks your stomach covers it clearly.

For most people, this slowing effect is perceptible within the first few weeks of treatment, even at the starting 0.25mg dose.

Step 2: the gut-brain conversation that quiets hunger

GLP-1 receptors are not only in the stomach. They are also in the hypothalamus, the part of the brain that regulates appetite and energy balance. Semaglutide activates both sets of receptors at once, which is why the reduction in hunger feels more fundamental than simply feeling full after a big meal. The brain receives a signal that energy needs are met, and the drive to seek food decreases.

This dual action also affects the reward response to food. Many people on Wegovy report that cravings for high-calorie foods reduce, not just their capacity to eat them. That shift can feel unfamiliar at first. A question our prescribers hear regularly is whether this change is permanent, it is not; appetite typically returns to its previous level when treatment stops, which is why ongoing clinical assessment matters throughout.

For a broader view of what semaglutide does across the body beyond the digestive system, this page on Wegovy's full-body effects goes into more detail. The semaglutide overview also covers the pharmacology in plain terms.

STEP 1 trial data, published in the New England Journal of Medicine, reported an average weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose, a result driven by these stomach and brain mechanisms working together.

Step 3: the stomach-related side effects, and when to take them seriously

Because Wegovy slows gastric emptying and activates gut receptors, the stomach's adjustment period is real. Nausea is the most frequently reported side effect, particularly after starting treatment or moving to a higher dose. Bloating, indigestion, constipation, and reflux are also common, and our page on how Wegovy behaves in the stomach explains why these effects tend to be most pronounced in the first one to two weeks at any given dose, then settle for most people as the body adapts.

Eating smaller portions more slowly, avoiding fatty or heavily spiced meals, and staying well hydrated all help. The dose titration schedule (starting low and increasing gradually) exists specifically to reduce the intensity of these effects.

One side effect that requires more than patience is severe stomach pain, especially pain that is persistent and radiates to the back. In January 2026 the MHRA issued a Drug Safety Update for GLP-1 medicines highlighting acute pancreatitis as an infrequent but serious risk; anyone experiencing those specific symptoms should stop the injection and seek medical attention promptly. You can report any suspected side effects via the MHRA Yellow Card scheme. For a focused guide to stomach pain specifically, this page on Wegovy and stomach pain covers the full range of symptoms and when each warrants action.

Wegovy is not suitable during pregnancy, while breastfeeding, or for anyone under 18; a prescriber reviews these and other contraindications at consultation. If you are thinking about whether Wegovy could be appropriate for you, starting a free consultation with our prescribers is the place to begin. The Wegovy overview page also sets out the licence, eligibility and the process in full.